In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates

被引：1

作者：

Mandras, Narcisa ^{[1
]}

Roana, Janira ^{[1
]}

Scalas, Daniela ^{[1
]}

Fucale, Giacomo ^{[2
]}

Allizond, Valeria ^{[1
]}

Banche, Giuliana ^{[1
]}

Barbui, Anna ^{[3
]}

Vigni, Nicolo Li ^{[4
]}

Newell, Vance A. ^{[5
]}

Cuffini, Anna Maria ^{[1
]}

Tullio, Vivian ^{[1
]}

机构：

[1] Univ Turin, Div Microbiol, Dept Publ Hlth & Paediat, Turin, Italy

[2] CTO CRF Hosp, Anal Lab & Microbiol, Turin, Italy

[3] S Giovanni Battista Hosp, Microbiol Lab, Turin, Italy

[4] Infermi Hosp, Anal Lab & Microbiol, Biella, Italy

[5] Giles Sci Inc, Santa Barbara, CA USA

来源：

NEW MICROBIOLOGICA | 2015年 / 38卷 / 04期

关键词：

Yeasts; Yeast-like fungi; Fluconazole; Voriconazole; Susceptibility testing; SUSCEPTIBILITIES; ISAVUCONAZOLE; SURVEILLANCE; SACCHAROMYCES; VIRULENCE; STRAINS;

D O I：

暂无

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The risk of opportunistic infections caused by non-Candida yeasts and yeast-like fungi is increasingly common, mainly in immunocompromised patients. Appropriate first-line therapy has not been defined and standardized, mainly due to the low number of cases reported. To improve empirical treatment guidelines, we describe the susceptibility profile to fluconazole and voriconazole of 176 non-Candida yeasts and yeast-like fungi collected from hospitals in Piedmont, North West Italy from January 2009 to December 2013. The results showed that most isolates are susceptible to voriconazole (94%), but less susceptible to fluconazole (78%), suggesting that voriconazole could be used as first-line therapy in infections caused by these fungi.

引用

页码：583 / 587

页数：5

共 21 条

[1]

[Anonymous], 2009, M44A2 CLSI

[2]

[Anonymous], COLD SPRING HARB PER

[3] ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of rare invasive yeast infections [J].